Ed Kaye preps a sur­pris­ing ex­it from Sarep­ta, spurring chat­ter about a pos­si­ble sale

On­ly sev­en months af­ter Ed Kaye won the right to drop “in­ter­im” from the CEO ti­tle at Sarep­ta $SRPT, he’s now plan­ning his ex­it.

In a sur­prise move for even the most hard-bit­ten com­pa­ny ob­servers — who have seen the re­volv­ing door out­side the CEO’s of­fice turn be­fore — Kaye an­nounced dur­ing Thurs­day’s quar­ter­ly call with an­a­lysts that he’ll be leav­ing, in the mean­time fo­cus­ing on “the next se­ries of key ini­tia­tives for Sarep­ta. These key ini­tia­tives in­clude ap­proval of Ex­ondys in Eu­rope, the ad­vance­ment of our next-gen­er­a­tion PP­MO chem­istry in­to the clin­ic. And fi­nal­ly, next-gen­er­a­tion ther­a­pies for DMD such as gene ther­a­py.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER